Tarperprumig

DRUG2 trials

Sponsors

Alexion Pharmaceuticals Inc., Alexion Pharmaceuticals, Inc.

Conditions

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisAnti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis

Phase 2

Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

RecruitingNCT07160608

Alexion Pharmaceuticals, Inc.Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Start: 2025-11-26End: 2028-02-14Target: 75Updated: 2026-06-16

Phase 2, Randomized, Double-Blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Tarperprumig in Adult Participants with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

RecruitingCTIS2025-521706-17-00

Alexion Pharmaceuticals Inc.Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis

Start: 2025-11-25Target: 21Updated: 2025-12-12